Apoptosis in prostatic adenocarcinoma following complete androgen ablation

Urologia Internationalis

Volumn 60, Issue SUPPL. 1, 1998, Pages 25-30

  Montironi, Rodolfo ^a   Pomante, R ^a   Diamanti, L ^a   Magi Galluzzi, C ^b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b RUSH MEDICAL COLLEGE   (United States)

Author keywords

Apoptosis; Complete androgen ablation; Prostate adenocarcinoma

Indexed keywords

ANTIANDROGEN; EOSIN; HEMATOXYLIN;

ADULT; AGED; APOPTOSIS; CELL DEATH; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; INVOLUTION; MALE; PREOPERATIVE CARE; PRIORITY JOURNAL; PROSTATE; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SIGNAL TRANSDUCTION; STAIN;

EID: 0031914480     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000056542     Document Type: Conference Paper

References (22)

1. Armas OA, Aprikian AG, Melamed J, Cordon-Cardo C, Cohen DW, Erlandson R, Fair WR, Reuter VE: Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 1994;18:979-991.
2. Têtu B: Morphologic changes induced by neoadjuvant combination therapy on prostatic tissue and prostatic cancer. Endocr Related Cancer 1996;3:165-170.
3. Montironi R, Magi-Galluzzi C, Muzzonigro G, Prete E, Polito M, Fabris G: Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate, prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Clin Pathol 1994;47:906-913.
4. Magi-Galluzzi C, Montironi R, Giannulis I, Diamanti L, Scarpelli M, Muzzonigro G, Polito M: Prostatic invasive adenocarcinoma. Effect of combination endocrine therapy (LHRH agonist and flutamide) on the expression and location of proliferating cell nuclear antigen (PCNA). Pathol Res Pract 1993;189:1154-1160.
5. Gaffney EF: The extent of apoptosis in different types of high grade prostatic carcinoma. Histopathology 1994;25:269-273.
6. Magi-Galluzzi C, Mishra R, Fiorentino M, Montironi R, Yao H, Capodieci P, Wishnow K, Kaplan I, Stork PJS, Loda M: Mitogen-activated protein kinase phosphatase-1 is overexpressed in prostate cancer and is inversely related to apoptosis. Lab Invest 1997;76:37-51.
7. Montironi R, Collan Y, Scarpelli M, Sisti S, Barbatelli G, Carnevali A, Pisani E, Mariuzzi GM: Reproducibility of mitotic counts and identification of mitotic figures in malignant glial tumors. Appl Pathol 1988;6:258-265.
8. Montironi R, Magi-Galluzzi C, Fabris G: Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation. Pathol Res Pract 1995;191:873-880.
9. Bostwick DG, Brawer MK: Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 1987;59:788-794.
10. Colombel M, Olsson CA, Ng P-Y, Buttyan R: Hormone-regulated apoptosis results from reentry of differentiated prostate cells into a defective cell cycle. Cancer Res 1992;52:4313-4319.
11. Denmeade SR, Lin XS, Isaacs J: Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996;28:251-265.
12. Furuya Y, Isaacs JT: Differential gene regulation during programmed death (apoptosis) versus proliferation of prostatic glandular cells induced by androgen manipulation. Endocrinology 1993;133:2660-2666.
13. Helpap B: Treated prostatic carcinoma. Histological, immunohistochemical and cell kinetic studies. Appl Pathol 1985;3:320-341.
14. Stiens R, Helpap B, Weissbach L: Quantitative Untersuchungen zum Zellverlust in Prostatakarzinomen: Klinisch-morphologische Aspekte. Verh Dtsch Ges Urol 1981;32:73-74.
15. English HF, Kyprianou N, Isaacs JT: Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 1989;15:233-250.
16. Kyprianou N, Bains AK, Jacobs SC: Induction of apoptosis in androgen-independent human prostate cancer cells undergoing thymineless death. Prostate 1994;25:66-75.
17. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hasieh J-T: Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-6944.
18. Magi-Calluzzi C, Montironi R, Cangi MG, Loda M: Expression of mitogen-activated protein kinases and mitogen-activated protein kinase phosphatase-1 in high-grade prostatic intraepithelial neoplasia. Virchow's Arch, in press.
19. Loda M, Capodieci P, Mishra R, Yao H, Corless C, Grigioni W, Wang Y, Magi-Galluzzi C, Stork PJ: Expression of MAP kinase phosphatase-1 (MKP-1) in the early phases of human epithelial carcinogenesis. Am J Pathol 1996;149:1553-1564.
20. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270:1326-1331.
21. Leav I, Magi-Galluzzi C, Ziar J, Stork PJ, Ho S-M, Loda M: Mitogen-activated protein kinase and mitogen-activated kinase phosphatase-1 expression in the Noble rat model of sex hormone-induced prostatic dysplasia and carcinoma. Lab Invest 1996;75:361-370.
22. Netto G, Sarkis A, Cordon-Cardo C, Fuks Z, Reuter VE: Evaluation of programmed cell death (PCD) in human benign prostatic epithelium. PIN and prostatic adenocarcinoma following total androgen ablation (abstract). Mod Pathol 1994;7:80.